Home Current Issue Previous Issues Published Ahead-of-Print Collections For Authors Journal Info
Skip Navigation LinksHome > January 2, 2008 - Volume 22 - Issue 1 > First phase I clinical trial of an HIV-1 subtype D gp140 env...
AIDS:
doi: 10.1097/QAD.0b013e3282f174ed
Research Letters

First phase I clinical trial of an HIV-1 subtype D gp140 envelope protein vaccine: immune activity induced in all study participants

Hurwitz, Julia La,b,d; Lockey, Timothy Da,c; Jones, Barta,b; Freiden, Pamelab; Sealy, Roberta,b; Coleman, Johnc; Howlett, Nannab; Branum, Kristenb; Slobod, Karen Sb,e

Collapse Box

Abstract

To combat HIV-1 diversity, we are developing a multienvelope vaccine (comprising DNA, vaccinia virus and protein vectors). Toward this goal, we conducted a phase I clinical trial of EnvPro, a gp140 protein formulated in alum. The vaccine was well tolerated and elicited an immune response in every trial participant.

© 2008 Lippincott Williams & Wilkins, Inc.

Login